michelcarroll/llama2-earnings-stock-prediction-fine-tune huggingface dataset:
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah, sure. I can take that one. So a couple of things. One is to remember that this year, I would say we had a little bit of our capital shift to right, just trying to purposely map that up against the schedule.
So I think that's one thing to keep in mind. And then we're in that last year before launch. So the capital in '22, I would think of it as a quarterly rate of around $300 million. That is going to start to tee up on the back half.
That's probably a good range.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
I'd see that tick up as a relative outlier. It is a function of larger than normal cash balances being held in our correspondent bank that hopefully will not necessarily be the case as much going forward. Predominantly from the standpoint of deploying that liquidity into core loans or to a lesser extent securities both the cash in our core funding.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah. Well, when we looked at consensus, it was obviously hard for us to know whether or not a weakening dollar had been picked up. We thought it probably hadn't in most people's forecasts that we published a few weeks ago, but as I said, if you were to use average January exchange rates for last year, revenues would have been $1.6 billion higher and costs would have been $1.1 billion higher. So as you work your numbers, I think you definitely have to think about the impact of the weak dollar. It also impacts why we're sticking with a $31 billion cost target for '22, which we think is $1 billion harder than what it was previously. And among that $1.6 billion of revenue uplift, it's roughly half and half across noninterest income and net interest income.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Hi, good morning. Thanks for taking my question. Just a question, Tom, you hinted that from the second half you're going to stop talking about drop-through rates and start talking about a margin recovery. What would -- what signals that sort of change in language, that change in mentality? And I'm sure you're aware that your European counterparts kind of dropped the drop-through language in this year and have already turned to that kind of margin guidance profile. Anything we should think different about Aramark that they still seeing some drop-through months maybe compared to your European peers?

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
I Hope that helps.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
So from our Investor Day, we talked about the fact that we're going to see growth there. We think it's valuable to our customers. We are already seeing revenue. We're seeing a lot of interest in having a lot of discussions. It provides them data on. Where the car is? The health of that car and it can also provide them information to look at the cargo, that's there safety implications. So a lot of positives for them, those discussions are going well, but we expected modest growth during this three-year planning period.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah. So John, I'll start on the answer there. The way that we have optimized our capital allocation for the very first year has us spending dollars in the dry gas Utica and the Montage assets A, because of their economic benefit; and B, it's going to benefit the SWN legacy assets by us gaining that incremental operational and technical knowledge drilling those Utica wells. So that was a little bit of the added push there. So in '21, the Montage asset liquids volumes will decline some. But as we always talk about, we rack and stack based on highest economics and we will -- we will allocate capital to the Montage liquids-rich assets as we continue the development over time.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Sure. Vijit, maybe I can take that. Our market share is close to about 30% of the total market right now. And maybe I can just take this opportunity to clarify the earlier question on the comments from our side as well. In terms of flown traffic, how market flown passengers have been growing because we do keep a good track of those numbers as well. So as I see those numbers for the month of June, for example, the flown passengers market was about 23% recovery, about $95 million flown passengers. And July 1 to 4, for example, was about 36%. And then subsequently, in the subsequent weeks of July, it has only been increasing and has gone to about 50%, 55% as well in the last few days. And average daily departures has also been sort of increasing month-on-month from May onwards. May was 29%, June, 33%; and July 1 to 4 was about 44%. And our recovery on the flown passengers actually has been ahead of the market. The market was growing at -- recovery was at 36% on flown and we were at 41% like-for-like for the first 4 days of July. And similarly, for June, when -- while market was at 23%, and we were at 26%. So just to clarify that a little bit more. And this is more like an absolute like-to-like comparison, so that there is no confusion. And I've already shared the market share number broadly as well.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Sure. So I think there's maybe a couple of ways to approach that problem. So first of all, every car that we sell is certified. It's Carvana certified. And our certification process was patterned off of some of the luxury manufacturers' certification processes. And so the cars that we deliver to customers are of that kind of -- that quality. The specific brand certified preowned is generally reserved for the combination of kind of franchise dealers and oftentimes kind of the branded OEM warranty that gets associated with that sale, although that's not always necessarily a condition of the brand of certified preowned.
So I think that we do believe that we're breaking into that market by building a brand of delivering very high-quality cars and by building a logistics network and infrastructure of reconditioning centers that are able to certify cars to that same quality. So that's our goal. But the particular brand is generally protected by -- or for franchise dealers.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Well, you know, I don't think we're prepared to quantify it today, but certainly, there will be an increase in expenses as we move forward, a portion of which is management-labor around shift supervisors, as well as some of our team members in the restaurant.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah. So we took -- in my prepared remarks I mentioned that we did take a charge in the quarter, or we anticipate in the quarter -- in the fourth quarter taking a charge related to closing out a foreign pension plan, and so it's non-cash charge in the quarter. So that hits us. And then general professional fees that we're spending across a myriad of things that we're working primarily around M&A, due diligence and things of that nature. We would expect to come back down as we look at next year.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Hey, Ryan.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
You got it.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
That's part of the uncertainty here, but what we have referenced in the past is -- for North America anyway, Ducker is a third party we use, and last update they showed for '22 versus '21 on window shipments was low-single-digit growth, around the two-plus percent range.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Thanks. So just a couple. So on the biosimilars, can you just talk about -- I know that this is a partnership model, but how should we think about your net economics, and how these three opportunities you've identified, what kind of margins they'll have relative to your overall Generic margins, given the shared economics? So that's number one.
Then number two is, you've talked about other programs, other biosimilar programs. When are you going to be in a position to identify those other opportunities? And do you expect those other opportunities to have better economics or similar economics to Avastin and the G-CSFs? And then lastly, is there anything that you can add on the Copaxone generic? And is this still part of your expectation that you expect that opportunity to bear fruit later this year? Thank you.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Okay. Thanks for taking my questions. Obviously, phenomenal numbers in the second quarter and this conversion to a hybrid producer has obviously been very impressive. Clearly, record high prices also helping. So my question is, as far as your strategy in terms of the capital allocation commentary, $1 billion is nice. That's basically the free cash you generated this quarter. What specifically do you plan to do with what's probably going to be $4 billion of cash over the next 12 months? If you can be a little more specific? And if you could read in some commentary regarding where shareholder returns fits into the equation? Thanks.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
You know, what -- maybe, Sean will take the first question. I'll take the second.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Not really offset. So we think there's going to be some inflation that's already started to come in, as Dee mentioned. We think as she said that price cost is going to be neutral for the year. We think most of that's going to be noise. We're going to get a little better mix moving forward and then we get through the inventory writedowns. And where we're at now is similar to where we're likely to be moving forward. So it's not going to be a big shift due to cost increases that we foresee at this point.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah, Mario, on the Consulting side, we've continued to have a relatively strong performance there. We're seeing obviously a lot of work with what are the major trends in technology, digital transformation, cloud optimization, cybersecurity, things of those nature. Those are really the big ones for us. As you know, we tend to focus our Consulting business on our largest, most complex clients, and they have those issues in earnest that a lot of our other size clients as well. But we've seen really good performance broadly geographically and spread nicely across those couple of areas. And I would throw in strategic sourcing and cost optimization into that Consulting mix as well that is a strong practice for us.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
I think you're going to, it might take longer than that, Michael, we started comping up pretty good in May and June, we kind of in the fall season we peaked I think August-September, Jack, 45, 47 or something like that in the core business.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Thanks for the question.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah. Thanks for letting me back in the queue. Just a follow-up. On the FMG, just going back to my 2017 notes, it looked like FMG was, we'll call it, 40 megs of capacity there, and that was around CAD20 million of EBITDA. So, is the expectation that at some point in 2021 this could come back, or could we see altered kind of agreements there?

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Hey. Good morning, everyone.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes. So let me talk about the EU market, and I'll also mention other markets. So we have undertaken commercial assessments in both Europe and other parts of the world, including Asia. We're encouraged by the opportunities.
There's certainly the great need for other potential graft sources, other cell therapies for allogeneic stem cell transplant patients in Europe and also in certain areas throughout the world, including Asia. So we're certainly very focused on launching omidubicel in the U.S., we feel very confident in our strategy and our execution plans to do it, and we're currently assessing what a potential path to launch could be in Europe and in Asia. The clinical study was designed as a head-to-head comparator. So we do recognize the applicability of that study in certain parts of the world, specifically in Europe.
Let me turn --

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
I think the thing to bear in mind there, not necessarily expenses, but the impact on our business. In the first quarter, I commented on the impact on our advisory businesses and some of the P&C program businesses, things like that, that were more severely impacted. Those had a relatively stronger first quarter before they were impacted late in the first quarter and through the balance of the year. So that's why we caution against the quarterly comparables. But that's where we felt the slowdown in those select businesses.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah. Maybe -- this is Bob, David. And maybe I'll start, and I'll ask Ralph to add some comments. You know what, we've continue to see pressure here in Hawaii on pricing. We haven't seen it too much on structure. It's been much more active in the mainland, primarily the West Coast where we have relationships with some direct relationships and a lot of relationships with other banks. And it just seems to be quite active that people are doing transactions out there, that we've been able to participate in. I expect we'll see more volume here over time, but there will be some headwinds, as I mentioned earlier, with a couple of large projects here paying off in Q4 on the CRE construction site.
But, Ralph, anything you'd add to that?

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Thanks. Good morning, everyone.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Tom, this is Frank. We would agree with you on that statement. And I would say in the areas where we've seen quite effective vaccination programs. In Israel, the healthcare system brought us directly to patients and our patients as opposed to patients having to go to it. In Portugal, the distribution was directly to our clinics. And in Puerto Rico, it was a National Guard effort. It was sort of a public local use of sort of the National Guard to try to make sure there was broad distribution to the population.
So our -- the work that Bill Valle and the team has done and Cam Lynch in D.C. to try to get vaccine delivered directly to our clinics, both for our clinics and the rest of the renal community, has been one of the central efforts that's been going on. And we're still hopeful that we will get there. But it has been plagued by a lot of logistical and I think political changes.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Well, it's really -- I'll address the two examples I gave. So in the steerage one where we're moving work, it's really more quarterly, so it's a constant look at that. We have a formula for doing that, and then we are reimbursed more regularly. It's not a once-a-year catch-up and that's much better for us for a lot of reasons, and not just for more regular rev req, but also for accounting purposes and so on, for both of us, and that's a better approach.
On the M&A, obviously, that would be somewhat invisible to you because when we do a deal, what it just means is that we get paid more than we would have historically a little -- some of the premium over what our renegotiated rates would be for the volume that clearly has moved from that hospital to us, our hospital outreach business. So you're not going to really see that, and again, that's going to be a regular monthly, quarterly thing, not a catch-up.

    Prediction (one of UP, DOWN, SAME): SAME